Tag - CRNX

Developments

Crinetics gets FDA rare pediatric disease designation for congenital hyperinsulinism

The FDA granted Crinetics Pharmaceuticals’ (NASDAQ:CRNX) CRN04777 rare pediatric disease designation for the treatment of congenital hyperinsulinism. Congenital hyperinsulinism occurs when infants are born with life...

September 21, 2020

Developments

Crinetics Pharma’s paltusotine gets FDA orphan drug designation for acromegaly

The FDA granted Crinetics Pharmaceuticals’ (NASDAQ:CRNX) paltusotine orphan drug designation for the treatment of acromegaly, a disease usually caused by a benign growth hormone-secreting tumor in the brain’s pituitary...

July 8, 2020

Markets

Roth starts Crinetics Pharma at buy; PT $37

Roth Capital Partners launched coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a “buy” rating and $37 price target. The stock closed at $21.91 on Dec. 20. Crinetics is a clinical-stage pharmaceutical company...

December 23, 2019

Tag - CRNX

Crinetics gets FDA rare pediatric disease designation for congenital hyperinsulinism

Crinetics Pharma’s paltusotine gets FDA orphan drug designation for acromegaly

Roth starts Crinetics Pharma at buy; PT $37

General

More